Akimoto S, Inomiya H, Furuya Y, Akakura K, Ito H
Department of Urology, School of Medicine, Chiba University, Chiba, Japan.
Eur Urol. 1998 Aug;34(2):142-7. doi: 10.1159/000019700.
The aim of the present study was to determine whether the serum levels of a bone formation marker, i.e., the carboxy-terminal propeptide of type I procollagen (PICP), and a bone resorption marker, i.e., the carboxy-terminal telopeptide of type I collagen (ICTP) have prognostic value in prostate cancer patients with bone metastasis, compared with alkaline phosphatase (ALP) and prostate-specific antigen (PSA).
The serum levels of PICP, ALP, ICTP and PSA were examined in 116 untreated prostate cancer patients (40 patients with bone metastasis, 76 patients without bone metastasis), and the prognoses of the patients with bone metastasis were evaluated using univariate and multivariate analyses.
The bone metastasis patients with low PICP or ALP values had significantly better outcomes compared to the bone metastasis patients with high PICP or ALP values. A multivariate analysis of PICP, ICTP, ALP, PSA and the patients' age revealed that PICP and patients' age were important prognostic factors for survival. The pretreatment levels of ICTP and PSA did not show any substantial relation to the prognosis of these patients.
The results suggest that the pretreatment serum bone formation marker is an important prognostic indicator for prostate cancer patients with bone metastasis.
本研究旨在确定与碱性磷酸酶（ALP）和前列腺特异性抗原（PSA）相比，骨形成标志物即I型前胶原羧基末端前肽（PICP）和骨吸收标志物即I型胶原羧基末端肽（ICTP）的血清水平在前列腺癌骨转移患者中是否具有预后价值。
检测了116例未经治疗的前列腺癌患者（40例有骨转移，76例无骨转移）的血清PICP、ALP、ICTP和PSA水平，并采用单因素和多因素分析评估骨转移患者的预后。
与PICP或ALP值高的骨转移患者相比，PICP或ALP值低的骨转移患者预后明显更好。对PICP、ICTP、ALP、PSA和患者年龄进行多因素分析发现，PICP和患者年龄是生存的重要预后因素。ICTP和PSA的治疗前水平与这些患者的预后没有任何实质性关系。
结果表明，治疗前血清骨形成标志物是前列腺癌骨转移患者的重要预后指标。
